Zacks Small-Cap Research

Zacks Investment Research Page 2 scr.zacks.com INITIATING COVERAGE We are initiating coverage of CEL-SCI Corporation (NYSE: CVM) with a $14.00 price target based on our estimates for a 2021 US and 2022 EU launch of lead compound Multikine in squamous cell … ................
................